Cardiovascular outcomes in patients with locally advanced and metastatic prostate cancer treated with luteinising-hormone-releasing-hormone agonists or transdermal oestrogen: The randomised, phase 2 MRC PATCH trial (PR09)

The Lancet Oncology

Volumn 14, Issue 4, 2013, Pages 306-316

  Langley, Ruth E ^a,b   Cafferty, Fay H ^a   Alhasso, Abdulla A ^c   Rosen, Stuart D ^d   Sundaram, Subramanian Kanaga ^e   Freeman, Suzanne C ^a   Pollock, Philip ^f   Jinks, Rachel C ^a   Godsland, Ian F ^g   Kockelbergh, Roger ^h   Clarke, Noel W ⁱ   Kynaston, Howard G ^j   Parmar, Mahesh K B ^a   Abel, Paul D ^k  

^a MRC CLINICAL TRIALS UNIT   (United Kingdom)

^b ROYAL SUSSEX COUNTY HOSPITAL   (United Kingdom)

^c BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^d ROYAL BROMPTON HOSPITAL   (United Kingdom)

^e MID YORKSHIRE HOSPITALS NHS TRUST   (United Kingdom)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

^g IMPERIAL COLLEGE LONDON   (United Kingdom)

^h LEICESTER GENERAL HOSPITAL   (United Kingdom)

ⁱ CHRISTIE HOSPITAL   (United Kingdom)

^j CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

^k IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; ESTROGEN; GLUCOSE; GONADORELIN AGONIST; TESTOSTERONE;

ABDOMINAL PAIN; ACUTE CORONARY SYNDROME; ADULT; ADVANCED CANCER; AGED; ANXIETY; APPETITE; ARTERY EMBOLISM; ARTICLE; BLOOD PRESSURE; CANCER HORMONE THERAPY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CONCENTRATION LOSS; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEPRESSION; DIASTOLIC BLOOD PRESSURE; DIET RESTRICTION; DISEASE COURSE; DIZZINESS; DRUG INDUCED HEADACHE; DRUG SELF ADMINISTRATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPEPSIA; ECZEMA; EDEMA; ERECTILE DYSFUNCTION; ERYTHEMA; FATIGUE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GYNECOMASTIA; HAIR; HEART FAILURE; HEART PALPITATION; HOT FLUSH; HUMAN; HYPERGLYCEMIA; INSOMNIA; IRRITABILITY; LIBIDO; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTICENTER STUDY; NAUSEA; OCCLUSIVE CEREBROVASCULAR DISEASE; OPEN STUDY; PARESTHESIA; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN PIGMENTATION; SKIN TOXICITY; SWEATING; THORAX PAIN; URINE RETENTION; URTICARIA; VENOUS THROMBOEMBOLISM; VOMITING; WEIGHT CHANGE;

AGED; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; CARDIOVASCULAR DISEASES; DISEASE-FREE SURVIVAL; DRUG TOXICITY; ESTROGENS; HOT FLASHES; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; RECEPTORS, LHRH;

EID: 84875813346     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(13)70025-1     Document Type: Article

References (39)

1. Worldwide cancer statistics Cancer Research UK, (accessed Jan 29, 2013). http://info.cancerresearchuk.org/cancerstats/world/.
2. Shahinian VB, Kuo YF, Gilbert SM Reimbursement policy and androgen-deprivation therapy for prostate cancer. N Engl J Med 2010, 363:1822-1832.
3. Pagliarulo V, Bracarda S, Eisenberger MA, et al. Contemporary role of androgen deprivation therapy for prostate cancer. Eur Urol 2012, 61:11-25.
4. Freedland SJ, Eastham J, Shore N Androgen deprivation therapy and estrogen deficiency induced adverse effects in the treatment of prostate cancer. Prostate Cancer Prostatic Dis 2009, 12:333-338.
5. Lee H, McGovern K, Finkelstein JS, Smith MR Changes in bone mineral density and body composition during initial and long-term gonadotropin-releasing hormone agonist treatment for prostate carcinoma. Cancer 2005, 104:1633-1637.
6. Wadhwa VK, Weston R, Parr NJ Frequency of zoledronic acid to prevent further bone loss in osteoporotic patients undergoing androgen deprivation therapy for prostate cancer. BJU Int 2010, 105:1082-1088.
7. Smith MR, Lee WC, Brandman J, Wang Q, Botteman M, Pashos CL Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol 2005, 23:7897-7903.
8. Abrahamsen B, Nielsen MF, Eskildsen P, Andersen JT, Walter S, Brixen K Fracture risk in Danish men with prostate cancer: a nationwide register study. BJU Int 2007, 100:749-754.
9. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005, 352:154-164.
10. Alibhai SM, Duong-Hua M, Sutradhar R, et al. Impact of androgen deprivation therapy on cardiovascular disease and diabetes. J Clin Oncol 2009, 27:3452-3458.
11. Saylor PJ, Smith MR Metabolic complications of androgen deprivation therapy for prostate cancer. J Urol 2009, 181:1998-2006.
12. Keating NL, O'Malley AJ, Smith MR Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006, 24:4448-4456.
13. Keating NL, O'Malley AJ, Freedland SJ, Smith MR Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst 2010, 102:39-46.
14. Levine GN, D'Amico AV, Berger P, et al. Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. Circulation 2010, 121:833-840.
15. Byar DP Proceedings: the Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate. Cancer 1973, 32:1126-1130.
16. von Schoultz B, Carlstrom K, Collste L, et al. Estrogen therapy and liver function-metabolic effects of oral and parenteral administration. Prostate 1989, 14:389-395.
17. Henriksson P, Blomback M, Eriksson A, Stege R, Carlstrom K Effect of parenteral oestrogen on the coagulation system in patients with prostatic carcinoma. Br J Urol 1990, 65:282-285.
18. Ockrim J Transdermal oestradiol therapy for the treatment of advanced prostate cancer 2003, Imperial College, London, MD thesis.
19. Langley RE, Godsland IF, Kynaston H, et al. Early hormonal data from a multicentre phase II trial using transdermal oestrogen patches as first-line hormonal therapy in patients with locally advanced or metastatic prostate cancer. BJU Int 2008, 102:442-445.
20. Hedlund PO, Ala-Opas M, Brekkan E, et al. Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer-Scandinavian Prostatic Cancer Group (SPCG) study no. 5. Scand J Urol Nephrol 2002, 36:405-413.
21. Ockrim JL, Lalani EN, Laniado ME, Carter SS, Abel PD Transdermal estradiol therapy for advanced prostate cancer-forward to the past?. J Urol 2003, 169:1735-1737.
22. Blackard CE, Doe RP, Mellinger GT, Byar DP Incidence of cardiovascular disease and death in patients receiving diethylstilbestrol for carcinoma of the prostate. Cancer 1970, 26:249-256.
23. Van Hemelrijck M, Garmo H, Holmberg L, et al. Absolute and relative risk of cardiovascular disease in men with prostate cancer: results from the population-based PCBaSe Sweden. J Clin Oncol 2010, 28:3448-3456.
24. Tsai HK, D'Amico AV, Sadetsky N, Chen MH, Carroll PR Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst 2007, 99:1516-1524.
25. Punnen S, Cooperberg MR, Sadetsky N, Carroll PR Androgen deprivation therapy and cardiovascular risk. J Clin Oncol 2011, 29:3510-3516.
26. Nguyen PL, Je Y, Schutz FA, et al. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. JAMA 2011, 306:2359-2366.
27. Norman G, Dean ME, Langley RE, et al. Parenteral oestrogen in the treatment of prostate cancer: a systematic review. Br J Cancer 2008, 98:697-707.
28. Bracamonte MP, Miller VM Vascular effects of estrogens: arterial protection versus venous thrombotic risk. Trends Endocrinol Metab 2001, 12:204-209.
29. Hedlund PO, Damber JE, Hagerman I, et al. Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer: part 2. Final evaluation of the Scandinavian Prostatic Cancer Group (SPCG) study no. 5. Scand J Urol Nephrol 2008, 42:220-229.
30. Hedlund PO, Johansson R, Damber JE, et al. Significance of pretreatment cardiovascular morbidity as a risk factor during treatment with parenteral oestrogen or combined androgen deprivation of 915 patients with metastasized prostate cancer: evaluation of cardiovascular events in a randomized trial. Scand J Urol Nephrol 2011, 45:346-353.
31. Smith MR, Finkelstein JS, McGovern FJ, et al. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab 2002, 87:599-603.
32. Eri LM, Urdal P, Bechensteen AG Effects of the luteinizing hormone-releasing hormone agonist leuprolide on lipoproteins, fibrinogen and plasminogen activator inhibitor in patients with benign prostatic hyperplasia. J Urol 1995, 154:100-104.
33. Torimoto K, Samma S, Kagebayashi Y, et al. The effects of androgen deprivation therapy on lipid metabolism and body composition in Japanese patients with prostate cancer. Jpn J Clin Oncol 2011, 41:577-581.
34. Suzuki K, Nukui A, Hara Y, Morita T Glucose intolerance during hormonal therapy for prostate cancer. Prostate Cancer Prostatic Dis 2007, 10:384-387.
35. Dockery F, Bulpitt CJ, Agarwal S, Donaldson M, Rajkumar C Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia. Clin Sci (Lond) 2003, 104:195-201.
36. Smith MR Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab 2006, 91:1305-1308.
37. Smith MR, Lee H, McGovern F, et al. Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome. Cancer 2008, 112:2188-2194.
38. Henriksson P, Angelin B, Berglund L Hormonal regulation of serum Lp (a) levels. Opposite effects after estrogen treatment and orchidectomy in males with prostatic carcinoma. J Clin Invest 1992, 89:1166-1171.
39. Godsland IF Oestrogens and insulin secretion. Diabetologia 2005, 48:2213-2220.